Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Prolinemia Type II
Homo sapiens
Disease Pathway
Prolinemia Type II is caused by mutation in the pyrroline-5-carboxylate dehydrogenase gene (P5CDH) mitochondrial matrix NAD-dependent dehydrogenase. This dehydrogenase is a catalyst for converting pyrroline-5-carboxylate to glutamate in the proline degradation pathway. An enzyme defect causes accumulation of glycine, hydroxyproline and proline in the urine, ornithine in the serum and proline in plasma. Symptoms include mental retardation, acute and chronic renal failure, and seizures.
References
Prolinemia Type II References
Engelke, U., van der Graaf, M., Heerschap, A., Hoenderop, S., Moolenaar, S., Morava, E., Wevers, R. Handbook of 1H-NMR spectroscopy in inborn errors of metabolism: body fluid NMR spectroscopy and in vivo MR spectroscopy (2nd ed) (2007) p.83 Heilbronn: SPS Verlagsgesellschaft
Emery FA, Goldie L, Stern J: Hyperprolinaemia type 2. J Ment Defic Res. 1968 Sep;12(3):187-95. doi: 10.1111/j.1365-2788.1968.tb00258.x.
Pubmed: 4972625
Geraghty MT, Vaughn D, Nicholson AJ, Lin WW, Jimenez-Sanchez G, Obie C, Flynn MP, Valle D, Hu CA: Mutations in the Delta1-pyrroline 5-carboxylate dehydrogenase gene cause type II hyperprolinemia. Hum Mol Genet. 1998 Sep;7(9):1411-5. doi: 10.1093/hmg/7.9.1411.
Pubmed: 9700195
Selkoe DJ: Familial hyperprolinemia and mental retardation. A second metabolic type. Neurology. 1969 May;19(5):494-502. doi: 10.1212/wnl.19.5.494.
Pubmed: 5815222
Valle DL, Phang JM, Goodman SI: Type 2 hyperprolinemia: absence of delta1-pyrroline-5-carboxylic acid dehydrogenase activity. Science. 1974 Sep 20;185(4156):1053-4. doi: 10.1126/science.185.4156.1053.
Pubmed: 4369405
Mitsubuchi H, Nakamura K, Matsumoto S, Endo F: Biochemical and clinical features of hereditary hyperprolinemia. Pediatr Int. 2014 Aug;56(4):492-6. doi: 10.1111/ped.12420.
Pubmed: 24931297
Lehninger, A.L. Lehninger principles of biochemistry (4th ed.) (2005). New York: W.H Freeman.
Salway, J.G. Metabolism at a glance (3rd ed.) (2004). Alden, Mass.: Blackwell Pub.
Wu G, Bazer FW, Davis TA, Kim SW, Li P, Marc Rhoads J, Carey Satterfield M, Smith SB, Spencer TE, Yin Y: Arginine metabolism and nutrition in growth, health and disease. Amino Acids. 2009 May;37(1):153-68. doi: 10.1007/s00726-008-0210-y. Epub 2008 Nov 23.
Pubmed: 19030957
Wu G, Morris SM Jr: Arginine metabolism: nitric oxide and beyond. Biochem J. 1998 Nov 15;336 ( Pt 1):1-17. doi: 10.1042/bj3360001.
Pubmed: 9806879
Brandsch M: Transport of L-proline, L-proline-containing peptides and related drugs at mammalian epithelial cell membranes. Amino Acids. 2006 Sep;31(2):119-36. doi: 10.1007/s00726-006-0307-0. Epub 2006 Apr 20.
Pubmed: 16622594
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings